SpaceX Is Back Above Its IPO Price. Is It too Late to Buy the Stock?

SpaceX shares rebounded to about $145 after falling toward ~$104, supported by the Aug. 6 lockup expiration passing without heavy insider selling. The company’s Q2 revenue rose 92% YoY to $7.8B and the net loss narrowed to $541M from $1B, but the article flags execution risk around Starship’s next-gen reusable rocket and notes valuation is already demanding (P/S ~64 vs typical <2). Wall Street’s average price target is $235.69 (~+62% upside), but the author argues odds skew toward downside and recommends waiting for a better entry point.

Analysis

The market is treating the post-lockup tape as a real-time referendum on insider conviction, but in a tightly held name that interpretation is noisy: no selling can simply reflect transfer restrictions, tax planning, or the fact that liquidity is still too thin to absorb size. The more important mechanism is float scarcity, which can keep the stock levitated until a single negative catalyst forces repricing. At this valuation, the market is paying for a near-flawless cadence of Starship progress plus continued hyper-growth in the core business; that leaves very little buffer for execution slippage.

The key second-order effect is on public space proxies. If Starship slows, customers and government buyers will hedge toward alternate launch capacity, which is constructive for RKLB and, to a lesser extent, defense-space primes like LMT/NOC that can monetize orbital and national-security demand without binary technical risk. Conversely, if Starship keeps compounding test success, public competitors face a tougher fundraising and valuation backdrop because SpaceX sets the price ceiling for launch economics and raises the bar for every adjacent space narrative.

Contrarianly, the consensus may be underweighting how much of the current move is momentum plus scarcity rather than a fundamentally de-risked franchise. The falsifiers are clear: any failed Starship test, any sign that capex/AI spending re-accelerates losses, or any secondary sale that meaningfully increases supply. Over days, the stock can overshoot on sentiment; over 1-3 months, test cadence matters most; over 6-18 months, only sustained reusable-rocket execution can justify the multiple.

Key Decisions for Investors

• Fade SPCX strength via a defined-risk put spread into any rally above current levels; thesis is multiple compression if the next Starship milestone slips or secondary supply appears.
• Relative-value long RKLB vs. short SPCX on Starship delay risk: RKLB benefits from diversified launch demand if customers hedge away from SpaceX execution risk; invalidate if SpaceX posts repeated clean test results over the next 1-2 quarters.
• Use LMT or NOC as a lower-beta way to express continued orbital/space-spending growth; this is a better risk-adjusted long than chasing SPCX at a high sales multiple.
• Set a watch item on the next Starship test and any insider-secondary filing; if both are clean and growth stays >70% YoY for another quarter, the bear case weakens materially and the short should be reduced.